REG - Eco Animal Health Gp - Board Changes

ECO Animal HealthAnnouncement

31/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250131:nRSe3540Va&default-theme=true

RNS Number : 3540V  Eco Animal Health Group PLC  31 January 2025

31 January 2025

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Board Changes

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that Dr Andrew Jones, who joined the
Board as a Non-executive Director in 2017 and has served as Chairman of the
Board since 2019, has stated his intention to retire on 31(st) March 2025.

As part of a planned succession process, Dr Joachim Hasenmaier joined the
Board as a Non-executive Director in February 2024 and will be appointed as
Chairman of the Board of ECO on 31(st) March 2025.

Dr Hasenmaier is a highly experienced commercial leader with more than two
decades in the global animal health industry. From 2001 to 2019, he held a
variety of senior roles within the animal health division at Boehringer
Ingelheim, concluding as member of the Board of Managing Directors responsible
for the entire animal health division. During this time, he led successful
transformation initiatives including the integration of the former Sanofi
animal health business Merial, spearheaded key product launches and supported
rapid global growth and expansion.

Dr Andrew Jones stepped down as Chairman of the Nomination Committee on 30
January 2025 and Dr Hasenmaier was appointed as Chairman of the Nomination
Committee on the same day. On 31 March 2025, Dr Jones will also step down from
the Audit and Remuneration Committees.  There will be no further changes to
the composition of these committees.

Dr Andrew Jones, outgoing Chairman, commented:

"It has been a privilege to serve as Chairman of ECO Animal Health over the
past six years and to work alongside such a talented and dedicated team. After
several years as Chairman, I have decided the time is right to retire and I'm
delighted to be handing over to someone with such a wealth of experience and
expertise. Over the years, we have expanded ECO's global reach, built a robust
product portfolio, and laid the groundwork for a strong pipeline of innovative
solutions in animal health. Joachim is absolutely the right person to succeed
me as Chair, he has a wealth of commercial industry experience and, since
joining the Board as a Non-executive Director, has demonstrated solid
leadership and expertise."

Dr Joachim Hasenmaier, incoming Chairman, added:

"I am honoured to be appointed Chairman of ECO Animal Health. On behalf of the
Board, I would like to thank Andrew for his exceptional leadership, under
which ECO has taken great strides in innovation, global reach and product
development. ECO is moving into its important next phase with increased focus
on the commercialisation of its research and development pipeline. I look
forward to working with the Board and the management team to build on this
momentum and deliver value for all stakeholders."

 

-Ends-

For further information please contact:

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFLDLSIIVIE